FDA partners with advocacy groups, research organizations to fight Alzheimer's

04/10/2014 | FDA Voice blog

Hamburg

As society comes to grips with the personal, economic and social effects of Alzheimer's disease, the FDA remains determined to facilitate the discovery of effective treatments, FDA Commissioner Dr. Margaret Hamburg writes. The agency is participating in efforts to create a national plan to address the Alzheimer's disease crisis and is partnering on public-private initiatives and with advocacy groups and consortia in the Alzheimer’s community, she writes.

View Full Article in:

FDA Voice blog

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC